Unspecified & Vague Pain caused due to Fibromyalgia is characterised by widespread chronic pain, fatigue, reduced sleep quality and multiple tender points. Fibromyalgia is one of the major health issues in today’s time. Studies relating to Fibromyalgia have found that prevalence of chronic unspecified and vague body pain being present between 21-25%. The most difficult part is the intangibility. Due to this, the pain is complicated to manage.
Fibromyalgia and its prevalence are growing day by day. A recent study suggests that in the US, around 15% women are affected by Fibromyalgia. It is not just the United States that has been affected by the disease but Europe as well. An estimated overall prevalence of Fibromyalgia in Europe is about 7.7%. In fact it is affecting the entire world. Fibromyalgia is the third most prevalent disorder after low back pain and osteoarthritis. The most disheartening aspect of the disease is the astronomical economic costs that it comes with.
Fibromyalgia not only comes with challenging symptoms but brings along lot of economic and mental burden which the patient and their family members undergo.
Prevalence of comorbidities:
A higher prevalence of comorbidities had been displayed in FM patients. Apart from that, FM patients had six more yearly medical visits and had a higher average of work days missed. Furthermore, around 74% of the patients suffering from FM use non-steroidal anti-inflammatory drugs. Quite shockingly, the cost of pharmacological treatment amounts to only 8%.
Fibromyalgia through scaling:
It has been calculated that a minimal increase in Fibromyalgia impacts Questionnaire score. An increase in the Brief Pain Inventory score by one point (11-point Likert scale) increases costs of treatment. The higher the level of impact caused by the disease on a patients’ daily life, the lower the changes in these levels have to be to increase the costs dramatically. Furthermore, the prevalence of anxiety and depression significantly adds up to the total costs.